Literature DB >> 11238095

Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation.

L Belhassen1, G Pelle, S Sediame, D Bachir, C Carville, C Bucherer, C Lacombe, F Galacteros, S Adnot.   

Abstract

Interactions between the endothelium and erythrocytes may contribute to the vascular complications of sickle cell disease (SCD). Endothelium-derived nitric oxide (NO) plays a major role in the regulation of vasomotor tone in response to wall shear stress (WSS) variations and pharmacologic stimuli. However, little is known about endothelial NO production in patients with steady-state SCD. We investigated endothelial NO production in response to flow or vasoactive agonists in 16 homozygous patients with steady-state SCD and 15 controls. Flow-mediated dilation (FMD), arterial diameter changes in response to 100% oxygen inhalation, blood viscosity, and calculated WSS were determined in all patients and controls. At baseline, WSS was higher in SCD patients than in controls, whereas arterial diameter was similar. In patients with SCD, FMD was impaired (1.73% +/- 0.44% vs 3.97% +/- 0.24% in the controls, P <.001) and vasoconstriction in response to 100% oxygen was abolished. Using venous occlusion plethysmography, forearm blood flow (FBF) was evaluated in response to acetylcholine, nitro-monomethyl-L-arginine (L-NMMA), and sodium nitroprusside (SNP) in subgroups of 9 controls and 7 patients with SCD. Acetylcholine induced a significantly greater FBF increase in the patients (9.7 +/- 2.9 mL/min/100 mL of forearm volume vs 2.5 +/- 1.5 mL/min/100 mL in the controls, P <.001), whereas responses to L-NMMA and SNP were similar. These results suggest that endothelial dysfunction may prevent the arterial diameter of patients with SCD from adapting to chronic or acute shear stress elevations. This may contribute to the pathophysiology of vaso-occlusive crisis in patients with SCD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238095     DOI: 10.1182/blood.v97.6.1584

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

1.  Vasculature and kidney complications in sickle cell disease.

Authors:  Karl A Nath; Zvonimir S Katusic
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

2.  Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.

Authors:  Candice Bereal-Williams; Roberto F Machado; Vicki McGowan; Amy Chi; Christian J Hunter; Gregory J Kato; Lori Hunter; Carole K Dalby; Kristine Partovi Hauser; Anitaben Tailor; Richard O Cannon
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

4.  Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Authors:  Gregory J Kato; Matthew Hsieh; Roberto Machado; James Taylor; Jane Little; John A Butman; Tanya Lehky; John Tisdale; Mark T Gladwin
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

5.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Authors:  Dhananjay K Kaul; Xiao-du Liu; Hee-Yoon Chang; Ronald L Nagel; Mary E Fabry
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Renal vascular resistance in sickle cell painful crisis.

Authors:  Birol Guvenc; Kairgeldy Aikimbaev; Cagatay Unsal; Erol Akgul; A Erol Akgul; Figen Binokay; Ayberk Besena
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

7.  Endothelial function in patients with sickle cell anemia during and after sickle cell crises.

Authors:  Arnon Blum; Shay Yeganeh; Aviva Peleg; Fina Vigder; Konstantin Kryuger; Ahmed Khatib; Khalid Khazim; Harold Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 8.  Sickle cell disease and nitric oxide: a paradigm shift?

Authors:  A Kyle Mack; Gregory J Kato
Journal:  Int J Biochem Cell Biol       Date:  2006-02-17       Impact factor: 5.085

9.  Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Authors:  Terika P Smith; Alyssa M Schlenz; Jeffrey C Schatz; Rangan Maitra; Sarah M Sweitzer
Journal:  Blood Cells Mol Dis       Date:  2014-11-26       Impact factor: 3.039

10.  Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.

Authors:  Dhananjay K Kaul; Xiaoqin Zhang; Trisha Dasgupta; Mary E Fabry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.